Nov 1, 2018
Medicines Development for Global Health (MDGH) is delighted to announce that it has received the 2018 AusBiotech and Johnson & Johnson Innovation Industry Excellence Award in the “Established Company of the Year Award” category.
Established in 2005, MDGH is dedicated to the development of affordable medicines and vaccines for neglected diseases prevalent in low- and middle-income countries. MDGH is a not-for-profit, social enterprise that uses all funds in excess of running costs to develop medicines and vaccines that may have limited commercial opportunity but address important unmet medical needs. In June 2018, MDGH achieved US FDA approval for moxidectin for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. River blindness is caused by a parasitic worm, Onchocerca volvulus. The disease manifests as severe itching, disfiguring skin conditions, and visual impairment, including permanent blindness, caused by the worm’s larvae (microfilariae).
Each year the AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards are presented at the AusBiotech national conference to recognise the highest achievers in the Australian life sciences. The Australian Established Company of the Year award is awarded to companies that have demonstrated significant corporate, commercial, and scientific achievements in the life sciences.
“We are delighted to receive this award in recognition of licensing moxidectin into Australia, raising the funds to complete development, and achieving FDA approval and a priority review voucher,” said Mark Sullivan, Founder and Managing Director of MDGH. “We’ve been working towards this goal for 13 years and it is wonderful for our organisation to receive such fantastic recognition for our efforts. We are very appreciative of Johnson & Johnson’s support of innovative companies and thank them for this award.”